Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial

The Lancet Neurology

Volumn 8, Issue 4, 2009, Pages 334-344

  Collinge, John ^a,b   Gorham, Michele ^a   Hudson, Fleur ^c   Kennedy, Angus ^a   Keogh, Geraldine ^b,c   Pal, Suvankar ^a,b   Rossor, Martin ^b   Rudge, Peter ^a   Siddique, Durre ^a,b   Spyer, Moira ^c   Thomas, Dafydd ^a,b   Walker, Sarah ^c   Webb, Tom ^a,b   Wroe, Steve ^a,b   Darbyshire, Janet ^c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPIRTINE; MEPACRINE; PENTOSAN POLYSULFATE;

ABDOMINAL ABSCESS; ABNORMAL BEHAVIOR; ADOLESCENT; ADULT; AGED; AGITATION; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONVULSION; DELIRIUM; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRY SKIN; DYSPHAGIA; FEMALE; HEMATEMESIS; HUMAN; LACERATION; LIVER DYSFUNCTION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARESTHESIA; PRION DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SEIZURE; SIDE EFFECT; SKIN DISCOLORATION; SOMNOLENCE; SUICIDE ATTEMPT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PRION DISEASES; QUINACRINE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; YOUNG ADULT;

EID: 62149105940     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70049-3     Document Type: Article

References (36)

1. Collinge J. Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24 (2001) 519-550
2. Collinge J., Whitfield J., McKintosh E., et al. A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philos Trans R Soc Lond B Biol Sci 363 (2008) 3725-3739
3. Wroe S.J., Pal S., Siddique D., et al. Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368 (2006) 2061-2067
4. Mallucci G., and Collinge J. Rational targeting for prion therapeutics. Nat Rev Neurosci 6 (2005) 23-34
5. Trevitt C., and Collinge J. A systematic review of prion therapeutics in experimental models. Brain 129 (2006) 2241-2265
6. Doh-ura K., Ishikawa K., Murakami-Kubo I., et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 78 (2004) 4999-5006
7. Korth C., May B.C., Cohen F.E., and Prusiner S.B. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98 (2001) 9836-9841
8. Department of Health, Medical Research Council. Consumer workshop on clinical trials for CJD. http://www.uclh.nhs.uk/NR/rdonlyres/8BCBA2CA-D25B-44AB-95B8-A7527BD655B6/0/pdfcjd_workshop.pdf (accessed March 3, 2009).
9. Torgerson D.J., and Sibbald B. Understanding controlled trials-what is a patient preference trial?. BMJ 316 (1998) 360
10. WHO. Creutzfeldt-Jakob disease (CJD) and variant CJD (vCJD). www.who.int/entity/zoonoses/diseases/Creutzfeldt.pdf (accessed March 3, 2009).
11. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
12. Rosen W.G., Mohs R.C., and Davis K.L. A new rating-scale for Alzheimers disease. Am J Psychiatry 141 (1984) 1356-1364
13. Teasdale G., and Jennett B. Assessment of coma and impaired consciousness-practical scale. Lancet 2 (1974) 81-84
14. Morris J.C. The clinical dementia rating (CDR)-current version and scoring rules. Neurology 43 (1993) 2412-2414
15. Schneider L.S., Olin J.T., Doody R.S., et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord 11 (1997) S22-S32
16. Overall J.E., and Gorham D.R. The brief psychiatric rating scale. Psychol Rep 10 (1962) 799-812
17. Rankin J. Cerebral vascular accidents in patients over the age of 60. Scott Med J 2 (1957) 127-136
18. Mahoney F.I., and Barthel D. Functional evaluation: the Barthel index. MD State Medical J 14 (1965) 56-61
19. Cancer Therapy Evaluation Program. common toxicity criteria. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf (accessed March 3, 2009).
20. Rubin D.B. Multiple imputation for nonresponse in surveys (1987), Wiley, London
21. Otto M., Cepek L., Ratzka P., et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 62 (2004) 714-718
22. Haik S., Brandel J.P., Salomon D., et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 63 (2004) 2413-2415
23. Bertrand A., Martinez-Almoyna L., and De Broucker T. Hereditary Creutzfeldt-Jakob disease caused by a mutation at codon 200. Rev Neurol (Paris) 161 (2005) 351-354
24. Martinez-Lage J.F., Rabano A., Bermejo J., et al. Creutzfeldt-Jakob disease acquired via a dural graft: failure of therapy with quinacrine and chlorpromazine. Surg Neurol 64 (2005) 542-545
25. Scoazec J.Y., Krolak-Salmon P., Casez O., et al. Quinacrine-induced cytolytic hepatitis in sporadic Creutzfeldt-Jakob disease. Ann Neurol 53 (2003) 546-547
26. Kobayashi Y., Hirata K., Tanaka H., and Yamada T. Quinacrine administration to a patient with Creutzfeldt-Jakob disease who received a cadaveric dura mater graft-an EEG evaluation. Rinsho Shinkeigaku 43 (2003) 403-408
27. Nakajima M., Yamada T., Kusuhara T., et al. Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 17 (2004) 158-163
28. Satoh K., Shirabe S., Eguchi K., et al. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Mol Neurobiol 24 (2004) 873-875
29. Furlow Jr. T.W., Whitley R.J., and Wilmes F.J. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine. Lancet 2 (1982) 564-565
30. Imperiale D., Bortolotto S., Cucatto A., Schiffer P., Cassano D., and Buffa C. Levetiracetam control of myoclonus in a patient with creutzfeldt-jakob disease. Eur Neurol 49 (2003) 189-190
31. Terzano M.G., Montanari E., Calzetti S., Mancia D., and Lechi A. The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol 40 (1983) 555-559
32. Yung L., Huang Y., Lessard P., et al. Pharmacokinetics of quinacrine in the treatment of prion disease. BMC Infect Dis 4 (2004) 53
33. Shannon J.A., Earle D.P., Brodie B.B., Taggart J.V., and Berliner R.W. The pharmacological basis for the rational use of atracrine in the treatment of malaria. J Pharmacol Exp Ther 81 (1944) 307-330
34. Dubin N.H., Blake D.A., DiBlasi M.C., Parmley T.H., and King T.M. Pharmacokinetic studies on quinacrine following intrauterine administration to cynomolgus monkeys. Fertil Steril 38 (1982) 735-740
35. Dubin N.H., Strandberg J.D., Craft C.F., Parmley T.H., Blake D.A., and King T.M. Effect of intrauterine and intravascular quinacrine administration on histopathology, blood chemistry, and hematology in cynomolgus monkeys. Fertil Steril 38 (1982) 741-747
36. Gayrard V., Picard-Hagen N., Viguie C., Laroute V., Andreoletti O., and Toutain P.L. A possible pharmacological explanation for quinacrine failure to treat prion diseases: pharmacokinetic investigations in a ovine model of scrapie. Br J Pharmacol 144 (2005) 386-393